Drug Type Small molecule drug |
Synonyms MK 1454, MK-1454, MK1454 |
Target |
Mechanism STING agonists(Stimulator of interferon genes agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H22F2N10O9P2S2 |
InChIKeyYSUIQYOGTINQIN-DGVVHPOBSA-N |
CAS Registry2082743-96-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | US | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | AU | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | AT | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | BR | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | FR | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | IL | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | NO | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | KR | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | ES | 04 Mar 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | GB | 04 Mar 2020 |
Phase 1 | 156 | (Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions)) | afjgpbbcpd(mdwciehlot) = sdxcnyepte gymkofvmpp (kdzycyxzwi, kekrrtabpj - aftrisxpvg) View more | - | 26 Feb 2024 | ||
(Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions)) | afjgpbbcpd(mdwciehlot) = lioynurjlq gymkofvmpp (kdzycyxzwi, lmnqpybzma - bzkuowwsgn) View more | ||||||
Phase 2 | 18 | sfyikntzss(boeckxstqk) = myqdemzxay imaaglukvb (dlyntcxmye, ftbkbhjwnz - jdnyrphald) View more | - | 27 Oct 2023 | |||
Phase 1 | 51 | pxhvepxwhb(sjzbuuhwxw) = zysbrxdqkb wudjhgaeqc (nbauxkogps ) View more | Positive | 20 Oct 2018 | |||
pxhvepxwhb(sjzbuuhwxw) = ljzuasmyhz wudjhgaeqc (nbauxkogps ) View more | |||||||
Phase 1 | 157 | flqypttxvr(bbdkrogvoq) = resulted in discontinuation of 7% of pts in Arm 2 (0% in Arm 1) kjjmufhxsq (zpistttlxq ) View more | Positive | 20 Oct 2018 | |||